These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 18613275)

  • 1. Improved retroviral vector design results in sustained expression after adult gene therapy in mucopolysaccharidosis I mice.
    Herati RS; Ma X; Tittiger M; Ohlemiller KK; Kovacs A; Ponder KP
    J Gene Med; 2008 Sep; 10(9):972-82. PubMed ID: 18613275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of neonatal administration of a retroviral vector expressing alpha-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice.
    Chung S; Ma X; Liu Y; Lee D; Tittiger M; Ponder KP
    Mol Genet Metab; 2007 Feb; 90(2):181-92. PubMed ID: 16979922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation.
    Ma X; Liu Y; Tittiger M; Hennig A; Kovacs A; Popelka S; Wang B; Herati R; Bigg M; Ponder KP
    Mol Ther; 2007 May; 15(5):889-902. PubMed ID: 17311010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited transgene immune response and long-term expression of human alpha-L-iduronidase in young adult mice with mucopolysaccharidosis type I by liver-directed gene therapy.
    Di Domenico C; Di Napoli D; Gonzalez Y Reyero E; Lombardo A; Naldini L; Di Natale P
    Hum Gene Ther; 2006 Nov; 17(11):1112-21. PubMed ID: 17044753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy.
    Traas AM; Wang P; Ma X; Tittiger M; Schaller L; O'donnell P; Sleeper MM; Vite C; Herati R; Aguirre GD; Haskins M; Ponder KP
    Mol Ther; 2007 Aug; 15(8):1423-31. PubMed ID: 17519893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector.
    Di Domenico C; Villani GR; Di Napoli D; Reyero EG; Lombardo A; Naldini L; Di Natale P
    Hum Gene Ther; 2005 Jan; 16(1):81-90. PubMed ID: 15703491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver-directed neonatal gene therapy prevents cardiac, bone, ear, and eye disease in mucopolysaccharidosis I mice.
    Liu Y; Xu L; Hennig AK; Kovacs A; Fu A; Chung S; Lee D; Wang B; Herati RS; Mosinger Ogilvie J; Cai SR; Parker Ponder K
    Mol Ther; 2005 Jan; 11(1):35-47. PubMed ID: 15585404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A self-inactivating gamma-retroviral vector reduces manifestations of mucopolysaccharidosis I in mice.
    Metcalf JA; Ma X; Linders B; Wu S; Schambach A; Ohlemiller KK; Kovacs A; Bigg M; He L; Tollefsen DM; Ponder KP
    Mol Ther; 2010 Feb; 18(2):334-42. PubMed ID: 19844196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retroviral-vector-mediated gene therapy to mucopolysaccharidosis I mice improves sensorimotor impairments and other behavioral deficits.
    Baldo G; Wozniak DF; Ohlemiller KK; Zhang Y; Giugliani R; Ponder KP
    J Inherit Metab Dis; 2013 May; 36(3):499-512. PubMed ID: 22983812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow.
    Zheng Y; Rozengurt N; Ryazantsev S; Kohn DB; Satake N; Neufeld EF
    Mol Genet Metab; 2003 Aug; 79(4):233-44. PubMed ID: 12948739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector.
    Kobayashi H; Carbonaro D; Pepper K; Petersen D; Ge S; Jackson H; Shimada H; Moats R; Kohn DB
    Mol Ther; 2005 May; 11(5):776-89. PubMed ID: 15851016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucopolysaccharidosis I cats mount a cytotoxic T lymphocyte response after neonatal gene therapy that can be blocked with CTLA4-Ig.
    Ponder KP; Wang B; Wang P; Ma X; Herati R; Wang B; Cullen K; O'Donnell P; Ellinwood NM; Traas A; Primeau TM; Haskins ME
    Mol Ther; 2006 Jul; 14(1):5-13. PubMed ID: 16698321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene.
    Hartung SD; Frandsen JL; Pan D; Koniar BL; Graupman P; Gunther R; Low WC; Whitley CB; McIvor RS
    Mol Ther; 2004 Jun; 9(6):866-75. PubMed ID: 15194053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model.
    Hinderer C; Bell P; Louboutin JP; Katz N; Zhu Y; Lin G; Choa R; Bagel J; O'Donnell P; Fitzgerald CA; Langan T; Wang P; Casal ML; Haskins ME; Wilson JM
    Mol Genet Metab; 2016 Sep; 119(1-2):124-30. PubMed ID: 27386755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neonatal Systemic AAV Induces Tolerance to CNS Gene Therapy in MPS I Dogs and Nonhuman Primates.
    Hinderer C; Bell P; Louboutin JP; Zhu Y; Yu H; Lin G; Choa R; Gurda BL; Bagel J; O'Donnell P; Sikora T; Ruane T; Wang P; Tarantal AF; Casal ML; Haskins ME; Wilson JM
    Mol Ther; 2015 Aug; 23(8):1298-1307. PubMed ID: 26022732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro gene therapy of mucopolysaccharidosis type I by lentiviral vectors.
    Di Natale P; Di Domenico C; Villani GR; Lombardo A; Follenzi A; Naldini L
    Eur J Biochem; 2002 Jun; 269(11):2764-71. PubMed ID: 12047386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome.
    Wang D; Zhang W; Kalfa TA; Grabowski G; Davies S; Malik P; Pan D
    Proc Natl Acad Sci U S A; 2009 Nov; 106(47):19958-63. PubMed ID: 19903883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of α-L-iduronidase in mice with mucopolysaccharidosis type I.
    Osborn MJ; McElmurry RT; Lees CJ; DeFeo AP; Chen ZY; Kay MA; Naldini L; Freeman G; Tolar J; Blazar BR
    Mol Ther; 2011 Mar; 19(3):450-60. PubMed ID: 21081900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation.
    Wang D; Shukla C; Liu X; Schoeb TR; Clarke LA; Bedwell DM; Keeling KM
    Mol Genet Metab; 2010 Jan; 99(1):62-71. PubMed ID: 19751987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α- L-iduronidase gene-based therapy using the phiC31 system to treat mucopolysaccharidose type I mice.
    Stilhano RS; Martin PK; de Melo SM; Samoto VY; Peres GB; da Silva Michelacci YM; da Silva FH; Pereira VG; D'Almeida V; da Cruz AT; Jasiulionis MG; Han SW
    J Gene Med; 2015; 17(1-2):1-13. PubMed ID: 25597593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.